



Complement Therapeutics Ltd announces appointment of Dr Dennis Keefe as Chief Scientific Officer

London, England – 10th August 2022 – Complement Therapeutics Ltd (CTx), a preclinical stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases, announces the appointment of Dr Dennis Keefe as Chief Scientific Officer. Dennis will be responsible for developing and executing the Company's overall scientific and research strategy as it advances its innovative pipeline of assets addressing unmet needs in complement mediated diseases such as geographic atrophy due to dry age-related macular degeneration, a major cause of vision loss and blindness globally.

Dennis is an accomplished biopharmaceutical executive with over 15 year's experience in the sector. He is a skilled drug developer with comprehensive experience across multiple therapeutic platforms including biologics, small molecules, RNA medicines and gene therapy. Dennis was previously CSO of Prothelia where he was responsible for all preclinical and nonclinical development efforts. Prior to this role, Dennis held numerous roles of increasing responsibility at Millenium Pharmaceuticals, Shire Pharmaceuticals and Stealth Biotherapeutics, where he led the preclinical development of the ophthalmology pipeline. In addition to ophthalmology, Dennis brings significant expertise in autoimmune, neurodegenerative and rare disease drug development.

Dr Rafiq Hasan, CEO, Complement Therapeutics Ltd commented, "It is a real pleasure and a privilege to welcome Dennis to the CTx team. His expertise and experience in both complement mediated conditions and ophthalmology will be invaluable to the company as we drive development of our novel pipeline and analytics platform with the potential to have a tremendous impact on the quality of life of those affected with vision loss and blindness."

Dennis Keefe, Chief Scientific Officer, commented, "I am excited to be joining CTx at this juncture and look forward to working with the growing team to develop a portfolio of innovative treatments and medicines to address the significant unmet need in both ophthalmology and broader complement driven diseases."

Dennis has a PhD from Tufts University and an MBA from Northeastern University and will be based in Boston, MA.

-Ends-

For more information please contact:

Complement Therapeutics Ltd

Dr Rafiq Hasan, CEO

Email: rafiq@complementtx.com

Notes to Editor

About Complement Therapeutics Ltd

Complement Therapeutics (CTx) is an early stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases as well as developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform.

The Company is backed by Forbion and Biogeneration Ventures, two of Europe's leading investors and is based on the pioneering research of its founders into novel targets within the complement cascade and its quantification.

Our lead investigational product (CTx001) is a gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of blindness. Additional programmes will evaluate potential therapeutic opportunities in other complement-mediated conditions. The Company is also developing the CPM platform, which employs a unique methodology to quantify over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.